Metagenomi, Inc. Common Stock (AU: MGX) — Healthcare · Share Price, Chart & Market Data
About: Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.50 (+4.90%)
MGXMetagenomi, Inc. Common Stock
Loading watchlist status…
Trade MGX now
Metagenomi, Inc. Common Stock share price
MGX price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
27 Apr, 12:42 pm GMT+0
MGX price performance
0%
5D
13.636%
1M
-10.18%
YTD
-11.243%
1Y
MGX price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
AU rank
N/A
Sector Rank
N/A
Delayed
27 Apr, 12:42 pm GMT+0
MGX details
MGX Market Signals